Johnson & Johnson Forecasts $2.5 Billion In COVID-19 Vaccine Sales

Johnson & Johnson Forecasts $2.5 Billion In COVID-19 Vaccine Sales

Johnson & Johnson forecast $2.5 billion in 2021 sales of its COVID-19 vaccine. (File)

London:

Johnson & Johnson on Wednesday raised its overall revenue estimate for the year and forecast $2.5 billion in sales of its COVID-19 vaccine, which has fallen way behind rival shots from Pfizer and Moderna as the company deals with vaccine production issues and safety concerns.

Although Johnson & Johnson's shot was approved in the United States months after vaccines from Pfizer Inc and Moderna Inc, its vaccine outlook pales in comparison with its peers and reflects the widening gap in the vaccine race.

Pfizer and Moderna forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively.

The J&J shot, once touted as an important tool for vaccinations in hard-to-reach areas, has already delayed deliveries in the United States and Europe. It has also been linked to a very rare, potentially life-threatening blood-clotting condition.

J&J raised its expectations for full-year sales to a range of $93.8 billion to $94.6 billion including contribution from the single-dose vaccine, and to $91.3 billion-$92.1 billion for the rest of the business.

It had previously forecast sales to come in between $90.6 billion and $91.6 billion.

The outlook was driven by recovery in sales at its medical devices unit and higher demand for treatments such as psoriasis and Crohn's disease drug Stelara.

The company had recorded $164 million in vaccine sales in for the second quarter.

Pfizer Inc and Moderna Inc have forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively. Both shots were approved in the United States last year, while J&J's vaccine was approved this year.

Both companies expect to profit from their vaccines, while Johnson & Johnson has said it will make the vaccine available on a not-for-profit basis during the pandemic.

In the second quarter, J&J earned $2.48 per share, beating analysts' average estimate of $2.27 per share, according to IBES data from Refinitiv.

The company reported $23.31 billion in total sales, above the estimate of $22.21 billion.

Shares of the company rose 1% before the opening bell.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)

NDTV News

NDTV.com provides latest news from India and the world. Get today’s news headlines from Business, Technology, Bollywood, Cricket, videos, photos, live news coverage and exclusive breaking news from India.

https://www.ndtv.com/

Related news

Myanmar Junta Promises Elections In Two Years

Myanmar's junta chief said Sunday that elections would be held and a state of emergency lifted by August 2023, extending the military's initial timeline given when it deposed Aung San Suu Kyi six...

NDTV News

Border crisis an 'unprecedented, unmitigated disaster': Rep.

Border crisis an 'unprecedented, unmitigated disaster': Rep.

Louisiana Congressman Mike Johnson argues the migrant surge is a humanitarian, health and national security issue and says the Biden administration needs to step up 'immediately.' #FoxNews #FoxFriendsFirst Subscribe to Fox News! Watch more Fox New...

MTV turns 40!

MTV turns 40!

ABC News’ Will Ganss and Bruno del Granado look back at all the iconic moments that made MTV what it is today.

COVID-19: Data shows infections rise to 1 in 65 people for England.

COVID-19: Data shows infections rise to 1 in 65 people for England.

The data also shows hospitalisations among 15 to 24-year-olds are the highest they've been since the start of the pandemic across England. The Office for National Statistics data will limit confidence in the dashboard data which had shown a drop o...

Over 40 million people live in slavery worldwide - DW News.

Over 40 million people live in slavery worldwide - DW News.

More people are living in slavery today than at any other time in history. Slavery impacts over 40 million people worldwide, women and girls make up around 70 percent of the victims. In Pakistan, a lack of economic opportunities and education cont...

Tom Homan: ICE can no longer do their jobs

Tom Homan: ICE can no longer do their jobs

The former acting director of Immigration and Customs Enforcement discusses the Biden administration's border policies on ‘Fox & Friends’ Subscribe to Fox News! Watch more Fox News Video: Watch Fox News Channel Live: FOX News Channel (FNC) is a 24...

IN FULL: Kenya's President warns against 'vaccine nationalism'.

IN FULL: Kenya's President warns against 'vaccine nationalism'.

The President of Kenya says the "entire developing world" is fighting a battle with wealthy nations for vaccines. Uhuru Kenyatta has urged governments around the world to work together and put an end to "vaccine nationalism", warning that "nobody ...